Inclusion and exclusion criteria
prostate cancer, prostate
PROSTATE CANCER, PROSTATE, PROSTATIC DISEASE
Patients with suspected ILF after radiation will be recruited. Patients must have a BCF per Phoenix criteria at least two years after initial prostate cancer treatment, an intra-prostatic lesion with PSMA PET avidity (Standard Uptake Value (SUV) of 3.0 or greater on a diagnostic PSMA PET/CT), and no evidence of extra prostatic disease.All patients are required to have a prostate biopsy to confirm ILF at the time of enrolment and have no contraindications for HDR brachytherapy, general anaesthesia, PSMA PET/MRI or Lu-177 PSMA RLT. Contraindications for these procedures include having inadequate marrow function (absolute neutrophil count less than 1.5 × 10